Metal/N-Heterocyclic Carbene Complexes: Opportunities for the Development of Anticancer Metallodrugs
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metal/N-Heterocyclic Carbene Complexes: Opportunities for the Development of Anticancer Metallodrugs
Authors
Keywords
-
Journal
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 52, Issue 46, Pages 11976-11978
Publisher
Wiley
Online
2013-10-04
DOI
10.1002/anie.201306682
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gold(III) Complexes Containing N-Heterocyclic Carbene Ligands: Thiol “Switch-on” Fluorescent Probes and Anti-Cancer Agents
- (2013) Taotao Zou et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Antitumor trans-N-Heterocyclic Carbene–Amine–Pt(II) Complexes: Synthesis of Dinuclear Species and Exploratory Investigations of DNA Binding and Cytotoxicity Mechanisms
- (2013) Mélanie Chtchigrovsky et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fluorescent silver(i) and gold(i)–N-heterocyclic carbene complexes with cytotoxic properties: mechanistic insights
- (2013) Anna Citta et al. Metallomics
- Anticancer Activity of Silver-N-Heterocyclic Carbene Complexes: Caspase-Independent Induction of Apoptosis via Mitochondrial Apoptosis-Inducing Factor (AIF)
- (2012) Laure Eloy et al. ChemMedChem
- N-Heterocyclic carbene metal complexes in medicinal chemistry
- (2012) Luciano Oehninger et al. DALTON TRANSACTIONS
- Gold(I) Carbene Complexes Causing Thioredoxin 1 and Thioredoxin 2 Oxidation as Potential Anticancer Agents
- (2012) Esther Schuh et al. JOURNAL OF MEDICINAL CHEMISTRY
- CuAAC Functionalization of Azide-Tagged Copper(I)-NHCs Acting as Catalyst and Substrate
- (2012) Clémentine Gibard et al. ORGANOMETALLICS
- Challenges and Opportunities in the Development of Organometallic Anticancer Drugs
- (2012) Christian G. Hartinger et al. ORGANOMETALLICS
- A spontaneous gold(i)-azide alkyne cycloaddition reaction yields gold-peptide bioconjugates which overcome cisplatin resistance in a p53-mutant cancer cell line
- (2012) S. David Köster et al. Chemical Science
- Easy Derivatisation of Group 10 N-Heterocyclic Carbene Complexes and In Vitro Evaluation of an Anticancer Oestradiol Conjugate
- (2012) Edith Chardon et al. ChemPlusChem
- Direct functionalisation of group 10 N-heterocyclic carbene complexes for diversity enhancement
- (2011) Edith Chardon et al. CHEMICAL COMMUNICATIONS
- Cytotoxicity of Gold(I) N-Heterocyclic Carbene Complexes Assessed by Using Human Tumor Cell Lines
- (2011) Jennifer Weaver et al. CHEMISTRY-A EUROPEAN JOURNAL
- Comparative in Vitro Evaluation of N-Heterocyclic Carbene Gold(I) Complexes of the Benzimidazolylidene Type
- (2011) Riccardo Rubbiani et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective Uncoupling of Individual Mitochondria within a Cell Using a Mitochondria-Targeted Photoactivated Protonophore
- (2011) Susan Chalmers et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Gold compounds as therapeutic agents for human diseases
- (2011) Susan J. Berners-Price et al. Metallomics
- Advances in metal–carbene complexes as potent anti-cancer agents
- (2011) Arnaud Gautier et al. Metallomics
- One-step synthesis of composite vesicles: Direct polymerization and in situ over-oxidation of thiophene
- (2011) Hang Sun et al. Chemical Science
- Benzimidazol-2-ylidene Gold(I) Complexes Are Thioredoxin Reductase Inhibitors with Multiple Antitumor Properties
- (2010) Riccardo Rubbiani et al. JOURNAL OF MEDICINAL CHEMISTRY
- Mitochondria-Targeted Chemotherapeutics: The Rational Design of Gold(I)N-Heterocyclic Carbene Complexes That Are Selectively Toxic to Cancer Cells and Target Protein Selenols in Preference to Thiols
- (2008) James L. Hickey et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now